Spots Global Cancer Trial Database for Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Official Title: Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma

Study ID: NCT01462630

Conditions

Adult Angiosarcoma

Recurrent Adult Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma

Stage IV Adult Soft Tissue Sarcoma

Interventions

pazopanib hydrochloride

laboratory biomarker analysis

positron emission tomography

computed tomography

fludeoxyglucose F 18

Study Description

Brief Summary: This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) at 3 months and response rate defined as complete response (CR) and partial response (PR) in angiosarcoma patients treated with pazopanib. SECONDARY OBJECTIVES: I. To assess overall survival of patients treated with pazopanib. II. To gather more safety data for pazopanib in this patient population. III. To explore the ability of \[F-18\] fludeoxyglucose (FDG) (positron emission tomography \[PET\])/computed tomography (CT) imaging to assess response. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years.